<DOC>
	<DOCNO>NCT00002803</DOCNO>
	<brief_summary>RATIONALE : Sometimes neuroblastoma regress without treatment , sometimes additional treatment may necessary . Giving one chemotherapy drug surgery remove tumor may kill tumor cell . PURPOSE : Phase II trial study combination chemotherapy observation follow surgery treat infant neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Observation Following Surgery Treating Infants With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine incidence spontaneous regression localize neuroblastoma infant . II . Determine many infant neuroblastoma need chemotherapy . III . Evaluate time course regression radiologic criterion catecholamine metabolite . IV . Determine reliability risk estimation molecular characteristic ( N-myc amplification , CD44 , del 1p ) compare clinical criterion . V. Evaluate whether reduce therapeutic toxicity result decrease treatment-related death . VI . Correlate cytostatic drug level chemotherapy side effect . OUTLINE : All patient undergo resection primary tumor N-myc determination within 6 month age , unless critically ill , treat accord risk . Patients amplify N-myc indeterminate N-myc amplification risk feature treat per protocol GER-NB90 . Stage 4S patient critically ill thrombocytopenic receive doxorubicin , vincristine , cyclophosphamide 7 day . Patients amplification N-myc observe 6 month ( 12 18 month age ) . Patients minimal residual disease ( le 10 % diameter great 2-5 mm ) continue observation , residual disease disease progression undergo repeat biopsy . Patients whose biopsy indicate tumor regression also continue observation . All patient , include disease progression , treat per protocol GER-NB90 . PROJECTED ACCRUAL : 36-44 patient per year accrue ( 22-27 patient stag 1-3 , 8-10 patient stage 4S , 6-7 patient stage 4 neuroblastoma ) .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : See General Eligibility Criteria PATIENT CHARACTERISTICS : See General Eligibility Criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>